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The increasing incidence of infections caused by the rapid
development of microbial resistance to most of the known
antibiotics is a serious health problem. A number of factors
are responsible for mutations in the microbial genomes. Asmultidrug-resistant microbial strains proliferate, the necessity
for effective therapy has stimulated research on the synthesis
of novel antimicrobial compounds (Saleh et al., 2010).
Furthermore, tuberculosis is retrieving its place among poten-
tially fatal infectious lung disease as nearly one-third of the
world’s population is infected withMycobacterium tuberculosis
with approximately three million patients deceasing every year
out of which developing countries show the major share.
Moreover, in immunocompromised patients, tubular pathol-
ogy is often accompanied by bacterial infections and WHO
declared TB as a global health emergency and aimed at saving
14 million lives between 2006 and 2015 (World Health
Organization, 2009). The emergence of multi drug resistant
tuberculosis (MDR-TB) and extensively drug resistant tuber-
culosis (XDR-TB) has grown to be a desperate mission forArabian
2 D. Patel et al.medicinal chemists. This resistance crisis situation highlights
the need for screening new regimens involving novel mecha-
nism of action and synthetically feasible methods in order to
overcome pathways of bacterial drug resistance that is not
yet being adequately addressed.
As a continuous work on the synthesis of bioactive
coumarin-containing analogs (Patel et al., 2012), herein this
article we have reported the synthesis of coumarin-
based isoxazoles, pyrimidinthiones and pyrimidin-2-ones.
Isoxazoles are a class of heterocyclic compounds having a
wide range of pharmacological activities such as antinocicep-
tive (Karthikeyan et al., 2009), antioxidant, antibacterial
(Musad et al., 2011), anticancer (Kumbhare et al., 2012),
antithrombotic (Batra et al., 2004), analgesic, anti-
inﬂammatory (Karabasanagouda et al., 2009), antifungal
(Shailaja et al., 2011), herbicidal (Tibor et al., 1994) and
antiviral (Tomit et al., 1973).
Pyrimidinthiones have been reported for their antimicrobial
(Nagarajaiah et al., 2012), antiparasitic (Batra and Sharma,
1990), antitumor (Ozaki, 1984) and hypoglycemic (Baucer
et al., 1968) activities. During the past years, considerable evi-
dence has been accumulated to demonstrate the potential of
pyrimidin-2-ones incorporating a variety of biological activi-
ties such as anticancer, anti-inﬂammatory (Dinakaran et al.,
2012), analgesic (Russel et al., 1988), and antimicrobial
(Lanjewar et al., 2009).
In our previous work we have already synthesized cou-
marin based chalcones and further synthesized pyrazol, pyrim-
idine, cyanopyridine analogs (Patel et al., 2012) and some of
the compounds showed potent antimicrobial and antimy-
cobacterial activities. So, in the present study, further we have
synthesized isoxazoles, pyrimidinthiones, and pyrimidin-2-
ones from the same coumarin containing chalcones and new
analogs were tested for their bioactivities.2. Experimental
2.1. Analytical methods and instruments
Chemicals and solvents were obtained from commercial
sources and used as received throughout the investigation.
Melting points were determined in open capillaries on a
Veego electronic apparatus VMP-D (Veego Instrument
Corporation, Mumbai, India) and are uncorrected. IR spectra
(4000–400 cm1) of synthesized compounds were recorded on
a Shimadzu 8400-S FT-IR spectrophotometer (Shimadzu
India Pvt. Ltd., Mumbai, India) using KBr pellets. Thin layer
chromatography was performed on object glass slides
(2 · 7.5 cm) coated with silica gel-G and spots were visualized
under UV irradiation. 1H NMR and 13C NMR spectra were
recorded on a Varian 400 MHz model spectrometer (Varian
India Pvt. Ltd., Mumbai, India) using DMSO as a solvent
and TMS as an internal standard with 1H resonant frequency
of 400 MHz and 13C resonant frequency of 100 MHz. The 1H
NMR and 13C NMR chemical shifts were reported as parts per
million (ppm) downﬁeld from TMS (Me4Si). The splitting pat-
terns are designated as follows; s, singlet; br s, broad singlet; d,
doublet; t, triplet; q, quartet; m, multiplet. Mass spectra were
recorded on the JEOL SX-102 (EI) model. All new compounds
were subjected to elemental analysis using a Heraeus Carlo
Erba 1180 CHN analyzer (Hanau, Germany).Please cite this article in press as: Patel, D. et al., Synthesis and biological evaluation
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4-Hydroxycoumarin 1 (30 g, 0.185 mol) and 60 mL POCl3
were reﬂuxed for 1 h, cooled, and slowly poured into crushed
ice (700 g) with vigorous stirring. The solid was collected by ﬁl-
tration and washed successively with ice-water. Azeotropic dis-
tillation with n-hexane and hot ﬁltration of the by-product
(15 g, 17%) and then followed by evaporation of solvent,
and crystallization yielded (21.9 g, 65%) 4-chloro coumarin
with m.p. 87–89 C (Kova´cˇ et al., 2001).
2.3. 4-Chloro-3,40,30,400-tercoumarin (by-product) (3a)
Crystallization from acetic acid gave yellowish crystals, m.p.
322–327 C (Kova´cˇ et al., 2001).
2.4. Synthesis of 4-(4-acetyl-phenylamino)-chromen-2-one (4)
4-Chloro-chromen-2-one 3 (10.0 g, 0.055 mol) and 1-(4-amino-
phenyl)-ethanone (7.48 g, 0.055 mol) were dissolved in acetone
(250 mL). The reaction mixture was reﬂuxed for 6–8 h. Sodium
carbonate was added to neutralize HCl evolved during the
reaction mixture. After completion of the reaction, the mixture
was cooled and poured into crushed ice. The solid separated,
was ﬁltered, washed with water, dried and recrystallized from
ethanol to give compound 4. Yield: 82%. (Patel et al., 2012).
2.5. General procedure for the synthesis of chalcones 5(a–k)
Compound 4 (4.0 g, 0.014 mol) was dissolved in DMF (50 mL)
and appropriate aldehyde (for e.g. benzaldehyde – 1.54 g,
0.014 mol) was added with constant stirring at room tempera-
ture. Then KOH solution (40 wt%) was added to the reaction
mixture, which was stirred for 24 h at room temperature. On
completion of the reaction, the mixture was poured into
crushed ice and neutralized with HCl. The product was sepa-
rated out, ﬁltered, washed with water, dried and recrystallized
from ethanol to give compound 5a. m.p. 145–147 C. Similarly
other compounds 5(b–k) were synthesized. (Patel et al., 2012).
2.6. General procedure for the synthesis of isoxazoles 60(a–k)
Compound 5a (4.0 g, 0.010 mol) was dissolved in ethanol
(25 ml) and hydroxylamine hydrochloride (0.69 g, 0.010 mol)
was added to the solution. Then a solution of 40% KOH
was added to the reaction mixture and reﬂuxed for 10 h. The
progress of the reaction was monitored on TLC. After comple-
tion of the reaction, the mixture was cooled and poured into
crushed ice and neutralized with dilute HCl. The product
was separated out, ﬁltered, washed with water, dried and
recrystallized from alcohol to give 60a. Similarly other isoxa-
zoles 60(b–k) were synthesized.
2.6.1. 4-(4-(5-phenylisoxazol-3-yl)phenylamino)-2H-chromen-
2-one (60a)
Yield: 77%. m.p. 190–192 C; IR (KBr, cm1): 3278 (–NH),
1663 (C‚O of coumarin), 1588 (C‚N str. isoxazole); 1H
NMR (DMSO-d6, d, ppm): 8.76 (s, 1H, –NH), 7.81 (s, 1H, –
CH of isoxazole), 7.76 (d, J= 7.3 Hz, 1H, coumarin), 7.73–
7.18 (m, 9H, Ar–H), 6.75–6.58 (m, 3H, coumarin), 6.11 (s,of coumarin based isoxazoles, pyrimidinthiones and pyrimidin-2-ones. Arabian
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isoxazole), 164.27 (C‚N of isoxazoles), 162.45 (C‚O of cou-
marin), 149.37 (C–NH at coumarin), 149.33, 143.12, 133.46,
132.85, 130.97, 130.84, 130.19, 130.11, 129.80, 129.43, 128.12,
127.91, 125.24, 124.92, 119.50, 118.56, 118.24, 118.19, 92.49
(19C, Ar–C), 97.54 (CH of isoxazole); EMI-MS (m/z):
381.19 (M+); Anal. Calcd for C24H16N2O3: C, 75.78; H,
4.24; N, 7.36. Found: C, 75.83; H, 4.20; N, 7.31.
2.6.2. 4-(4-(5-(2,4-dichlorophenyl)isoxazol-3-yl)phenylamino)-
2H-chromen-2-one (60b)
Yield: 72%. m.p. 205–208 C; IR (KBr, cm1): 3280 (–NH),
1668 (C‚O of coumarin), 1583 (C‚N str. isoxazole), 788
(–Cl); 1H NMR (DMSO-d6, d, ppm): 8.82 (s, 1H, –NH), 7.77
(s, 1H, –CH of isoxazole), 7.74 (d, J= 7.3 Hz, 1H, coumarin),
7.71–7.13 (m, 7H, Ar–H), 6.72–6.61 (m, 3H, coumarin), 6.14
(s, 1H, coumarin); 13C NMR (DMSO-d6, d, ppm): 168.44
(C–O of isoxazole), 164.11 (C‚N of isoxazoles), 162.68
(C‚O of coumarin), 149.13 (C–NH at coumarin), 134.29
(C–Cl), 133.46 (C–Cl), 147.17, 142.21, 132.54, 132.43, 130.90,
130.45, 130.23, 129.56, 128.11, 128.10, 124.86, 124.75, 119.53,
118.61, 118.34, 117.33, 92.11 (17C, Ar–C), 97.41 (CH of isox-
azole); EMI-MS (m/z): 450.46 (M+); Anal. Calcd for
C24H14Cl2N2O3: C, 64.16; H, 3.14; N, 6.24. Found: C, 64.21;
H, 3.19; N, 6.18.
2.6.3. 4-(4-(5-p-tolylisoxazol-3-yl)phenylamino)-2H-chromen-
2-one (60c)
Yield: 64%. m.p. 231–233 C; IR (KBr, cm1): 3278 (–NH),
1671 (C‚O of coumarin), 1586 (C‚N str. isoxazole); 1H
NMR (DMSO-d6, d, ppm): 8.84 (s, 1H, –NH), 7.79 (s, 1H,
–CH of isoxazole), 7.71 (d, J= 7.2 Hz, 1H, coumarin), 7.68–
7.10 (m, 8H, Ar–H), 6.69–6.57 (m, 3H, coumarin), 6.19 (s,
1H, coumarin), 2.16 (s, 3H, Ph–CH3);
13C NMR (DMSO-d6,
d, ppm): 168.87 (C–O of isoxazole), 164.23 (C‚N of isoxa-
zoles), 162.55 (C‚O of coumarin), 148.96 (C–NH at cou-
marin), 138.62 (C–CH3 of phenyl), 147.17, 142.91, 133.44,
132.30, 130.89, 130.44, 129.91, 129.80, 129.67, 128.51, 128.32,
124.33, 124.45, 119.29, 118.21, 118.10, 117.32, 92.45 (18C,
Ar–C), 97.32 (CH of isoxazole), 21.13 (C–CH3 of phenyl);
EMI-MS (m/z): 395.12 (M+); Anal. Calcd for C25H18N2O3:
C, 76.13; H, 4.60; N, 7.10. Found: C, 76.18; H, 4.68; N, 7.03.
2.6.4. 4-(4-(5-(4-ﬂuorophenyl)isoxazol-3-yl)phenylamino)-2H-
chromen-2-one (60d)
Yield: 69%. m.p. 214–216 C; IR (KBr, cm1): 3282 (–NH),
1675 (C‚O of coumarin), 1581 (C‚N str. isoxazole), 1161
(C–F); 1H NMR (DMSO-d6, d, ppm): 8.80 (s, 1H, –NH),
7.75 (s, 1H, –CH of isoxazole), 7.73 (d, J= 7.1 Hz, 1H,
coumarin), 7.70–7.14 (m, 8H, Ar–H), 6.71–6.59 (m, 3H,
coumarin), 6.13 (s, 1H, coumarin); 13C NMR (DMSO-d6, d,
ppm): 168.75 (C–O of isoxazole), 168.11 (C–F), 164.29
(C‚N of isoxazoles), 162.42 (C‚O of coumarin), 148.85
(C–NH at coumarin), 148.10, 143.42, 133.80, 133.15, 132.90,
131.21, 130.20, 129.91, 129.61, 128.49, 128.23, 124.46, 124.21,
119.67, 118.23, 118.12, 117.67, 92.43 (18C, Ar–C), 97.10 (CH
of isoxazole); EMI-MS (m/z): 399.24 (M+); Anal. Calcd for
C24H15FN2O3: C, 72.36; H, 3.80; N, 7.03. Found: C, 72.31;
H, 3.86; N, 7.08.Please cite this article in press as: Patel, D. et al., Synthesis and biological evaluation
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2H-chromen-2-one (60e)
Yield: 72%. m.p. 229–231 C; IR (KBr, cm1): 3272 (–NH),
1665 (C‚O of coumarin), 1580 (C‚N str. isoxazole), 810
(–Cl); 1H NMR (DMSO-d6, d, ppm): 8.76 (s, 1H, –NH), 7.83
(s, 1H, –CH of isoxazole), 7.78 (d, J= 7.5 Hz, 1H, coumarin),
7.76–7.20 (m, 8H, Ar–H), 6.72–6.60 (m, 3H, coumarin), 6.14
(s, 1H, coumarin); 13C NMR (DMSO-d6, d, ppm): 167.93
(C–O of isoxazole), 164.21 (C‚N of isoxazoles), 162.13
(C‚O of coumarin), 148.78 (C–NH at coumarin), 133.57
(C–Cl), 148.77, 143.47, 133.69, 132.70, 131.12, 130.75,
129.95, 129.86, 129.40, 128.41, 128.37, 125.10, 124.65, 119.54,
118.86, 118.41, 117.21, 91.96 (18C, Ar–C), 97.67 (CH of isox-
azole); EMI-MS (m/z): 415.26 (M+); Anal. Calcd for
C24H15ClN2O3: C, 69.49; H, 3.64; N, 6.75. Found: C, 69.45;
H, 3.69; N, 6.65.
2.6.6. 4-(4-(5-(4-nitrophenyl)isoxazol-3-yl)phenylamino)-2H-
chromen-2-one (60f)
Yield: 63%. m.p. 262–264 C; IR (KBr, cm1): 3278 (–NH),
1668 (C‚O of coumarin), 1559 (N‚O str.), 1585 (C‚N str.
isoxazole); 1H NMR (DMSO-d6, d, ppm): 8.80 (s, 1H, –NH),
7.81 (s, 1H, –CH of isoxazole), 7.73 (d, J= 7.2 Hz, 1H,
coumarin), 7.70–7.10 (m, 8H, Ar–H), 6.75–6.63 (m, 3H,
coumarin), 6.11 (s, 1H, coumarin); 13C NMR (DMSO-d6, d,
ppm): 168.12 (C–O of isoxazole), 164.24 (C‚N of isoxazoles),
162.29 (C‚O of coumarin), 149.12 (C–NH at coumarin),
148.23 (C–NO2), 148.22, 143.29, 133.10, 132.85, 131.23,
130.34, 130.16, 129.70, 129.41, 128.92, 128.14, 123.90, 123.88,
119.65, 119.11, 118.18, 116.62, 92.27 (18C, Ar–C), 97.15 (CH
of isoxazole); EMI-MS (m/z): 426.14 (M+); Anal. Calcd for
C24H15N3O5: C, 67.76; H, 3.55; N, 9.88. Found: C, 67.71; H,
3.64; N, 9.84.
2.6.7. 4-(4-(5-(2-hydroxyphenyl)isoxazol-3-yl)phenylamino)-
2H-chromen-2-one (60g)
Yield: 75%. m.p. 228–230 C; IR (KBr, cm1): 3272 (–NH),
3244 (–OH), 1666 (C‚O of coumarin), 1581 (C‚N str. isox-
azole); 1H NMR (DMSO-d6, d, ppm): 8.82 (s, 1H, –NH), 7.79
(s, 1H, –CH of isoxazole), 7.75 (d, J= 7.1 Hz, 1H, coumarin),
7.72–7.15 (m, 8H, Ar–H), 6.71–6.62 (m, 3H, coumarin), 6.17
(s, 1H, coumarin), 4.42 (s, 1H, –OH); 13C NMR (DMSO-d6,
d, ppm): 168.19 (C–O of isoxazole), 164.37 (C‚N of isoxa-
zoles), 162.33 (C‚O of coumarin), 158.23 (C–OH), 148.82
(C–NH at coumarin), 147.69, 143.44, 133.59, 133.10, 131.56,
130.65, 129.87, 129.54, 129.26, 128.61, 127.54, 125.89, 124.81,
118.80, 118.78, 118.12, 117.40, 92.79 (18C, Ar–C), 97.11 (CH
of isoxazole); EMI-MS (m/z): 397.28 (M+); Anal. Calcd for
C24H16N2O4: C, 72.72; H, 4.07; N, 7.07. Found: C, 72.79; H,
4.11; N, 7.02.
2.6.8. 4-(4-(5-(2-bromophenyl)isoxazol-3-yl)phenylamino)-
2H-chromen-2-one (60h)
Yield: 61%. m.p. 249–252 C; IR (KBr, cm1): 3275 (–NH),
1669 (C‚O of coumarin), 1580 (C‚N str. isoxazole), 740
(–Br); 1H NMR (DMSO-d6, d, ppm): 8.78 (s, 1H, –NH), 7.82
(s, 1H, –CH of isoxazole), 7.76 (d, J= 7.4 Hz, 1H, coumarin),
7.74–7.19 (m, 8H, Ar–H), 6.65–6.53 (m, 3H, coumarin), 6.16
(s, 1H, coumarin); 13C NMR (DMSO-d6, d, ppm): 168.70of coumarin based isoxazoles, pyrimidinthiones and pyrimidin-2-ones. Arabian
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of coumarin), 149.14 (C–NH at coumarin), 121.77 (C–Br),
148.33, 143.10, 133.31, 132.15, 131.49, 130.60, 130.10, 129.43,
129.41, 128.30, 128.14, 125.08, 124.46, 119.69, 118.71, 118.40,
117.86, 92.66 (18C, Ar–C), 97.16 (CH of isoxazole); EMI-
MS (m/z): 460.25 (M+); Anal. Calcd for C24H15BrN2O3: C,
62.76; H, 3.29; N, 6.10. Found: C, 62.71; H, 3.40; N, 6.15.
2.6.9. 4-(4-(5-(4-methoxyphenyl)isoxazol-3-yl)phenylamino)-
2H-chromen-2-one (60i)
Yield: 79%. m.p. 217–219 C; IR (KBr, cm1): 3279 (–NH),
1665 (C‚O of coumarin), 1584 (C‚N str. isoxazole), 1271
(–OCH3);
1H NMR (DMSO-d6, d, ppm): 8.75 (s, 1H, –NH),
7.77 (s, 1H, –CH of isoxazole), 7.72 (d, J= 7.4 Hz, 1H,
coumarin), 7.70–7.12 (m, 8H, Ar–H), 6.68–6.51 (m, 3H,
coumarin), 6.21 (s, 1H, coumarin), 3.78 (s, 3H, –OCH3);
13C
NMR (DMSO-d6, d, ppm): 168.17 (C–O of isoxazole),
164.23 (C‚N of isoxazoles), 162.35 (C‚O of coumarin),
160.23 (C–OCH3), 148.84 (C–NH at coumarin), 147.97,
143.86, 132.81, 132.63, 131.15, 130.60, 130.25, 129.56, 129.33,
128.15, 128.10, 124.70, 124.25, 119.11, 118.76, 118.64, 117.43,
92.55 (18C, Ar–C), 56.28 (–OCH3), 96.32 (CH of isoxazole);
EMI-MS (m/z): 411.30 (M+); Anal. Calcd for C25H18N2O4:
C, 73.16; H, 4.42; N, 6.83. Found: C, 73.10; H, 4.49; N, 6.76.
2.6.10. 4-(4-(5-(3,4-dimethoxyphenyl)isoxazol-3-
yl)phenylamino)-2H-chromen-2-one (60j)
Yield: 70%. m.p. 269–271 C; IR (KBr, cm1): 3277 (–NH),
1662 (C‚O of coumarin), 1576 (C‚N str. isoxazole), 1275
(–OCH3);
1H NMR (DMSO-d6, d, ppm): 8.77 (s, 1H, –NH),
7.80 (s, 1H, –CH of isoxazole), 7.78 (d, J= 7.4 Hz, 1H,
coumarin), 7.75–7.18 (m, 7H, Ar–H), 6.64–6.49 (m, 3H,
coumarin), 6.18 (s, 1H, coumarin), 3.80 (s, 3H, –OCH3), 3.78
(s, 3H, –OCH3);
13C NMR (DMSO-d6, d, ppm): 168.54
(C–O of isoxazole), 164.35 (C‚N of isoxazoles), 162.49
(C‚O of coumarin), 160.44 (C–OCH3), 159.63 (C–OCH3),
149.16 (C–NH at coumarin), 148.24, 142.82, 133.59, 132.80,
131.11, 131.08, 130.95, 129.87, 128.70, 128.33, 124.65, 124.61,
119.50, 119.10, 118.43, 117.54, 92.28 (17C, Ar–C), 56.39
(–OCH3), 97.55 (CH of isoxazole); EMI-MS (m/z): 441.16
(M+); Anal. Calcd for C26H20N2O5: C, 70.90; H, 4.58; N,
6.36. Found: C, 70.94; H, 4.51; N, 6.30.
2.6.11. 4-(4-(5-(2,4-dihydroxyphenyl)isoxazol-3-
yl)phenylamino)-2H-chromen-2-one (60k)
Yield: 76%. m.p. 253–255 C; IR (KBr, cm1): 3286 (–NH),
3277 (–OH), 1666 (C‚O of coumarin), 1585 (C‚N str. isox-
azole); 1H NMR (DMSO-d6, d, ppm): 8.81 (s, 1H, –NH), 8.49
(s, 1H, –OH), 7.79 (s, 1H, -CH of isoxazole), 7.77 (d,
J= 7.4 Hz, 1H, coumarin), 7.72–7.139 (m, 7H, Ar–H), 6.69–
6.51 (m, 3H, coumarin), 6.20 (s, 1H, coumarin), 4.47 (s,1H,
–OH); 13C NMR (DMSO-d6, d, ppm): 168.53 (C–O of isoxa-
zole), 164.24 (C‚N of isoxazoles), 162.15 (C‚O of cou-
marin), 157.53 (C–OH), 157.21 (C–OH), 149.35 (C–NH at
coumarin), 148.58, 143.35, 133.21, 132.70, 131.55, 131.10,
130.63, 129.20, 128.86, 128.13, 125.10, 124.89, 119.56, 118.12,
118.07, 117.96, 92.19 (17C, Ar–C), 97.26 (CH of isoxazole);
EMI-MS (m/z): 413.67 (M+); Anal. Calcd for C24H16N2O5:Please cite this article in press as: Patel, D. et al., Synthesis and biological evaluation
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6.83.
2.7. General procedure for the synthesis of pyrimidinthiones
70(a–k)
Compound 5a (4.0 g, 0.01 mol) was dissolved in ethanol
(25 ml) and then thiourea (0.76 g, 0.01 mol) was added to the
solution. Then a solution of KOH (5 ml of 40%) was added
to the reaction mixture and reﬂuxed for 8 h. The progress of
the reaction was monitored on TLC. After completion of the
reaction, the mixture was then cooled and poured into crushed
ice and neutralized with dilute HCl. The product was separated
out, ﬁltered, washed with water, dried and recrystallized from
alcohol to give 70a. Similarly other pyrimidinthiones 70(b–k)
were synthesized.
2.7.1. 4-(4-(2-mercapto-6-phenylpyrimidin-4-yl)phenylamino)-
2H-chromen-2-one (70a)
Yield: 66%. m.p. 259–262 C; IR (KBr, cm1): 3280 (–NH),
1664 (C‚O of coumarin), 1571 (–SH str. of pyrimidine),
1563 (C‚N); 1H NMR (DMSO-d6, d, ppm): 8.77 (s, 1H,
–NH), 7.83 (d, J= 7.1 Hz, 1H, coumarin), 7.80–7.19 (m,
10H, Ar–H), 6.70–6.51 (m, 3H, coumarin), 6.19 (s, 1H,
coumarin), 3.38 (s, 1H, SH); 13C NMR (DMSO-d6, d, ppm):
176.11 (C–SH), 162.55 (C‚O of coumarin), 159.62, 159.21
(2C, pyrimidine), 149.10 (C–NH at coumarin), 113.56 (1C,
pyrimidine), 147.18, 142.56, 133.84, 133.11, 131.22, 131.10,
130.49, 130.13, 129.61, 129.13, 128.15, 128.11, 124.90, 124.77,
119.16, 118.61, 118.33, 117.34, 92.98 (19C, Ar–C); EMI-MS
(m/z): 424.32 (M+); Anal. Calcd for C25H17N3O2S: C, 70.90;
H, 4.05; N, 9.92. Found: C, 70.95; H, 4.11; N, 9.84.
2.7.2. 4-(4-(6-(2,4-dichlorophenyl)-2-mercaptopyrimidin-4-
yl)phenylamino)-2H-chromen-2-one (70b)
Yield: 69%. m.p. >300 C; IR (KBr, cm1): 3276 (–NH), 1667
(C‚O of coumarin), 1576 (–SH str. of pyrimidine), 1568
(C‚N), 824 (–Cl); 1H NMR (DMSO-d6, d, ppm): 8.79 (s,
1H, –NH), 7.87 (d, J= 7.4 Hz, 1H, coumarin), 7.77–7.14
(m, 8H, Ar–H), 6.68–6.56 (m, 3H, coumarin), 6.15 (s, 1H, cou-
marin), 3.35 (s, 1H, SH); 13C NMR (DMSO-d6, d, ppm):
176.37 (C–SH), 162.13 (C‚O of coumarin), 159.35, 159.48
(2C, pyrimidine), 149.61 (C–NH at coumarin), 113.69 (1C,
pyrimidine), 135.36 (C–Cl), 134.44 (C–Cl), 147.79, 143.65,
133.23, 132.56, 131.44, 130.30, 129.61, 129.30, 128.43, 127.11,
125.78, 124.13, 119.67, 118.23, 118.19, 118.26, 92.33 (17C,
Ar–C); EMI-MS (m/z): 493.14 (M+); Anal. Calcd for
C25H15Cl2N3O2S: C, 60.98; H, 3.07; N, 8.53. Found: C,
60.92; H, 3.14; N, 8.59.
2.7.3. 4-(4-(2-mercapto-6-p-tolylpyrimidin-4-yl)phenylamino)-
2H-chromen-2-one (70c)
Yield: 64%. m.p. >300 C; IR (KBr, cm1): 3280 (–NH), 1662
(C‚O of coumarin), 1573 (–SH str. of pyrimidine), 1562
(C‚N); 1H NMR (DMSO-d6, d, ppm): 8.84 (s, 1H, –NH),
7.83 (d, J= 7.2 Hz, 1H, coumarin), 7.75–7.19 (m, 9H,
Ar–H), 6.71–6.59 (m, 3H, coumarin), 6.18 (s, 1H, coumarin),
3.38 (s, 1H, SH), 2.21 (s, 3H, Ph–CH3);
13C NMR (DMSO-
d6, d, ppm): 176.89 (C–SH), 162.25 (C‚O of coumarin),
159.14, 159.11 (2C, pyrimidine), 148.81 (C–NH at coumarin),of coumarin based isoxazoles, pyrimidinthiones and pyrimidin-2-ones. Arabian
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143.64, 133.32, 132.47, 131.45, 130.53, 130.24, 129.73, 129.44,
128.31, 128.08, 125.31, 124.67, 119.78, 118.45, 118.43, 117.14,
92.91 (18C, Ar–C), 22.19 (C–CH3 of phenyl); EMI-MS
(m/z): 438.22 (M+); Anal. Calcd for C26H19N3O2S: C, 71.38;
H, 4.38; N, 9.60. Found: C, 71.45; H, 4.34; N, 9.66.
2.7.4. 4-(4-(6-(4-ﬂuorophenyl)-2-mercaptopyrimidin-4-
yl)phenylamino)-2H-chromen-2-one (70d)
Yield: 73%. m.p. 288–291 C; IR (KBr, cm1): 3276 (–NH),
1670 (C‚O of coumarin), 1579 (–SH str. of pyrimidine), 1565
(C‚N), 1164 (C–F); 1H NMR (DMSO-d6, d, ppm): 8.78 (s,
1H, –NH), 7.79 (d, J= 7.5 Hz, 1H, coumarin), 7.73–7.13 (m,
9H, Ar–H), 6.67–6.53 (m, 3H, coumarin), 6.21 (s, 1H, cou-
marin), 3.41 (s, 1H, SH); 13C NMR (DMSO-d6, d, ppm):
176.70 (C–SH), 168.41 (C–F), 162.11 (C‚O of coumarin),
160.05, 159.84 (2C, pyrimidine), 149.88 (C–NH at coumarin),
113.79 (1C, pyrimidine), 147.61, 143.54, 133.39, 132.15, 132.11,
131.04, 130.66, 129.97, 129.30, 128.45, 128.41, 124.53, 124.46,
119.60, 118.33, 118.20, 117.97, 92.35 (18C, Ar–C); EMI-MS
(m/z): 442.36 (M+); Anal. Calcd for C25H16FN3O2S: C, 68.01;
H, 3.65; N, 9.52. Found: C, 68.04; H, 3.71; N, 9.45.
2.7.5. 4-(4-(6-(4-chlorophenyl)-2-mercaptopyrimidin-4-
yl)phenylamino)-2H-chromen-2-one (70e)
Yield: 64%. mp 268–271 C; IR (KBr, cm1): 3283 (–NH), 1666
(C‚O of coumarin), 1574 (–SH str. of pyrimidine), 1561
(C‚N), 827 (–Cl); 1H NMR (DMSO-d6, d, ppm): 8.77 (s, 1H,
–NH), 7.81 (d, J= 7.1 Hz, 1H, coumarin), 7.76–7.19 (m, 9H,
Ar–H), 6.67–6.55 (m, 3H, coumarin), 6.16 (s, 1H, coumarin),
3.33 (s, 1H, SH); 13C NMR (DMSO-d6, d, ppm): 176.29 (C–
SH), 162.31 (C‚O of coumarin), 159.35, 159.20 (2C, pyrim-
idine), 149.16 (C–NH at coumarin), 113.69 (1C, pyrimidine),
134.39 (C–Cl), 147.15, 142.81, 133.54, 132.37, 131.47, 130.67,
130.15, 129.75, 129.38, 128.67, 128.53, 124.10, 123.54, 119.47,
118.80, 118.32, 117.10, 92.45 (18C, Ar–C); EMI-MS (m/z):
458.61 (M+); Anal. Calcd for C25H16ClN3O2S: C, 65.57; H,
3.52; N, 9.18. Found: C, 65.63; H, 3.48; N, 9.24.
2.7.6. 4-(4-(2-mercapto-6-(4-nitrophenyl)pyrimidin-4-
yl)phenylamino)-2H-chromen-2-one (70f)
Yield: 71%. m.p. >300 C; IR (KBr, cm1): 3276 (–NH), 1661
(C‚O of coumarin), 1571 (–SH str. of pyrimidine), 1565
(C‚N), 1558 (N‚O str.); 1H NMR (DMSO-d6, d, ppm): 8.79
(s, 1H, –NH), 7.85 (d, J= 7.1 Hz, 1H, coumarin), 7.81–7.24
(m, 9H, Ar–H), 6.69–6.59 (m, 3H, coumarin), 6.20 (s, 1H, cou-
marin), 3.35 (s, 1H, SH); 13C NMR (DMSO-d6, d, ppm): 176.47
(C–SH), 162.40 (C‚O of coumarin), 159.70, 159.39 (2C, pyrim-
idine), 149.24 (C–NH at coumarin), 148.56 (C–NO2), 113.18
(1C, pyrimidine), 147.69, 143.68, 133.87, 132.66, 131.52,
130.34, 129.97, 129.49, 129.13, 128.87, 128.56, 124.11, 123.13,
119.40, 118.87, 118.64, 117.84, 92.41 (18C, Ar–C); EMI-MS
(m/z): 469.15 (M+); Anal. Calcd for C25H16N4O4S: C, 64.09;
H, 3.44; N, 11.96. Found: C, 64.13; H, 3.41; N, 11.92.
2.7.7. 4-(4-(6-(2-hydroxyphenyl)-2-mercaptopyrimidin-4-
yl)phenylamino)-2H-chromen-2-one (70g)
Yield: 70%. m.p. 255–258 C; IR (KBr, cm1): 3278 (–NH),
3256 (-OH), 1660 (C‚O of coumarin), 1579 (–SH str. of
pyrimidine), 1565 (C‚N); 1H NMR (DMSO-d6, d, ppm):Please cite this article in press as: Patel, D. et al., Synthesis and biological evaluation
Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2014.06.0108.80 (s, 1H, –NH), 7.77 (d, J= 7.1 Hz, 1H, coumarin), 7.72–
7.12 (m, 9H, Ar–H), 6.70–6.58 (m, 3H, coumarin), 6.15 (s,
1H, coumarin), 4.60 (s, 1H, –OH), 3.37 (s, 1H, SH); 13C
NMR (DMSO-d6, d, ppm): 176.34 (C–SH), 162.97 (C‚O of
coumarin), 160.15, 159.76 (2C, pyrimidine), 158.47 (C–OH),
148.25 (C–NH at coumarin), 113.60 (1C, pyrimidine), 147.85,
143.96, 133.62, 133.15, 132.16, 131.62, 129.97, 129.15, 128.89,
128.66, 127.92, 124.73, 124.26, 119.25, 118.34, 118.31, 117.76,
93.04 (18C, Ar–C); EMI-MS (m/z): 440.15 (M+); Anal.
Calcd for C25H17N3O3S: C, 68.32; H, 3.90; N, 9.56. Found:
C, 68.36; H, 3.85; N, 9.50.
2.7.8. 4-(4-(6-(2-bromophenyl)-2-mercaptopyrimidin-4-
yl)phenylamino)-2H-chromen-2-one (70h)
Yield: 66%. m.p. >300 C; IR (KBr, cm1): 3275 (NH),
1662 (C‚O of coumarin), 1585 (SH str. of pyrimidine),
1563 (C‚N), 768 (Br); 1H NMR (DMSO-d6, d, ppm): 8.84
(s, 1H, –NH), 7.81 (d, J= 7.3 Hz, 1H, coumarin), 7.78–7.23
(m, 9H, Ar–H), 6.76–6.55 (m, 3H, coumarin), 6.10 (s, 1H, cou-
marin), 3.43 (s, 1H, SH); 13C NMR (DMSO-d6, d, ppm):
176.55 (C–SH), 163.08 (C‚O of coumarin), 160.11, 159.45
(2C, pyrimidine), 149.64 (C–NH at coumarin), 113.66 (1C,
pyrimidine), 121.73 (C–Br), 148.44, 143.23, 133.69, 132.10,
131.62, 130.66, 130.18, 129.32, 129.14, 128.32, 128.19, 124.73,
124.25, 119.73, 118.61, 118.22, 118.94, 92.15 (18C, Ar–C);
EMI-MS (m/z): 503.56 (M+); Anal. Calcd for
C25H16BrN3O2S: C, 59.77; H, 3.21; N, 8.36. Found: C,
59.81; H, 3.27; N, 8.32.
2.7.9. 4-(4-(2-mercapto-6-(4-methoxyphenyl)pyrimidin-4-
yl)phenylamino)-2H-chromen-2-one (70i)
Yield: 73%. m.p. 264–267 C; IR (KBr, cm1): 3281 (–NH),
1667 (C‚O of coumarin), 1579 (–SH str. of pyrimidine),
1566 (C‚N), 1271 (–OCH3);
1H NMR (DMSO-d6, d, ppm):
8.81 (s, 1H, –NH), 7.75 (d, J= 7.6 Hz, 1H, coumarin), 7.72–
7.15 (m, 9H, Ar–H), 6.73–6.57 (m, 3H, coumarin), 6.17 (s,
1H, coumarin), 3.71 (s, 3H, –OCH3), 3.41 (s, 1H, SH);
13C
NMR (DMSO-d6, d, ppm): 176.21 (C–SH), 162.45 (C‚O of
coumarin), 160.56 (C–OCH3), 159.24, 159.20 (2C, pyrimidine),
149.11 (C–NH at coumarin), 113.58 (1C, pyrimidine), 147.89,
143.20, 132.67, 132.54, 131.51, 131.18, 130.63, 129.72, 129.22,
128.61, 128.45, 124.44, 124.41, 119.67, 118.56, 118.24, 117.51,
92.69 (18C, Ar–C), 55.86 (–OCH3); EMI-MS (m/z): 438.65
(M+); Anal. Calcd for C26H19N3O3S: C, 68.86; H, 4.22; N,
9.27. Found: C, 68.90; H, 4.17; N, 9.30.
2.7.10. 4-(4-(6-(3,4-dimethoxyphenyl)-2-mercaptopyrimidin-4-
yl)phenylamino)-2H-chromen-2-one (70j)
Yield: 66%. m.p. 277–280 C; IR (KBr, cm1): 3278 (–NH),
1665 (C‚O of coumarin), 1574 (–SH str. of pyrimidine),
1560 (C‚N), 1287 (–OCH3);
1H NMR (DMSO-d6, d, ppm):
8.75 (s, 1H, –NH), 7.81 (d, J= 7.1 Hz, 1H, coumarin), 7.76–
7.21 (m, 8H, Ar–H), 6.65–6.53 (m, 3H, coumarin), 6.11 (s,
1H, coumarin), 3.84 (s, 3H, –OCH3), 3.81 (s, 3H, –OCH3),
3.32 (s, 1H, SH); 13C NMR (DMSO-d6, d, ppm): 176.55 (C–
SH), 162.31 (C‚O of coumarin), 161.04 (C–OCH3), 160.23
(C–OCH3), 159.29, 159.14 (2C, pyrimidine), 149.44 (C–NH
at coumarin), 113.40 (1C, pyrimidine), 147.53, 142.45,
133.29, 132.20, 131.27, 130.11, 129.54, 129.10, 128.43, 128.31,of coumarin based isoxazoles, pyrimidinthiones and pyrimidin-2-ones. Arabian
6 D. Patel et al.124.44, 124.21, 119.49, 119.34, 118.22, 117.86, 92.20 (17C, Ar–
C), 56.47 (–OCH3); EMI-MS (m/z): 484.63 (M+); Anal. Calcd
for C27H21N3O4S: C, 67.07; H, 4.38; N, 8.69. Found: C, 67.11;
H, 4.33; N, 8.62.
2.7.11. 4-(4-(6-(2,4-dihydroxyphenyl)-2-mercaptopyrimidin-4-
yl)phenylamino)-2H-chromen-2-one (70k)
Yield: 78%. m.p. >300 C; IR (KBr, cm1): 3286 (–NH), 3273
(–OH), 1660 (C‚O of coumarin), 1571 (–SH str. of pyrim-
idine), 1564 (C‚N); 1H NMR (DMSO-d6, d, ppm): 8.84 (s,
1H, –NH), 8.59 (s, 1H, –OH), 7.80 (d, J= 7.2 Hz, 1H, cou-
marin), 7.74–7.11 (m, 8H, Ar–H), 6.70–6.57 (m, 3H, cou-
marin), 6.24 (s, 1H, coumarin), 4.56 (s, 1H, –OH), 3.31 (s,
1H, SH); 13C NMR (DMSO-d6, d, ppm): 176.11 (C–SH),
162.45 (C‚O of coumarin), 159.66, 159.35 (2C, pyrimidine),
157.65 (C–OH), 157.34 (C–OH), 149.67 (C–NH at coumarin),
113.61 (1C, pyrimidine), 148.25, 142.94, 133.20, 132.12, 131.59,
130.27, 130.12, 129.95, 128.81, 128.41, 124.44, 124.27, 119.50,
118.42, 118.26, 117.89, 92.34 (17C, Ar–C); EMI-MS (m/z):
456.32 (M+); Anal. Calcd for C25H17N3O4S: C, 65.92; H,
3.76; N, 9.23. Found: C, 65.88; H, 3.82; N, 9.27.
2.8. General procedure for the synthesis of pyrimidin-2-ones
80(a–k)
Compound 5a (4.0 g, 0.01 mol) was dissolved in ethanol
(25 ml) and then urea (0.60 g, 0.01 mol) was added to the solu-
tion. Then a solution of KOH (5 ml of 40%) was added to the
reaction mixture and reﬂuxed for 8 h. The progress of the reac-
tion was monitored on TLC. After completion of the reaction,
the mixture was then cooled and poured into crushed ice and
neutralized with dilute HCl. The product was separated out,
ﬁltered, washed with water, dried and recrystallized from alco-
hol to give 80a. Similarly other pyrimidinthiones 80(b–k) were
synthesized.
2.8.1. 4-[4-(2-Hydroxy-6-phenyl-pyrimidin-4-yl)-
phenylamino]-chromen-2-one (80a)
Yield: 70%. m.p. >300 C; IR (KBr, cm1): 3277 (–NH), 3145
(–OH of pyrimidine), 1662 (C‚O of coumarin), 1558 (C‚N);
1H NMR (DMSO-d6, d, ppm): 9.83 (s, 1H, –OH), 8.81 (s, 1H,
–NH), 7.84 (d, J= 7.1 Hz, 1H, coumarin), 7.81–7.17 (m, 10H,
Ar–H), 6.66–6.53 (m, 3H, coumarin), 6.21 (s, 1H, coumarin);
13C NMR (DMSO-d6, d, ppm): 162.13 (C‚O of coumarin),
159.21, 159.10 (2C, pyrimidine), 157.23 (C–OH), 148.29 (C–
NH at coumarin), 112.93 (1C, pyrimidine), 148.11, 143.67,
132.90, 132.15, 131.52, 130.17, 130.10, 130.02, 129.83, 129.43,
128.51, 128.26, 125.12, 124.77, 119.43, 118.68, 118.32, 117.23,
92.33 (19C, Ar–C); EMI-MS (m/z): 408.45 (M+); Anal.
Calcd for C25H17N3O3: C, 73.70; H, 4.21; N, 10.31. Found:
C, 73.64; H, 4.30; N, 10.27.
2.8.2. 4-{4-[6-(2,4-Dichloro-phenyl)-2-hydroxy-pyrimidin-4-
yl]-phenylamino}-chromen-2-one (80b)
Yield: 67%. m.p. 253–255 C; IR (KBr, cm1): 3274 (-NH),
3141 (–OH of pyrimidine), 1666 (C‚O of coumarin), 1563
(C‚N), 810 (–Cl); 1H NMR (DMSO-d6, d, ppm): 9.87 (s,
1H, –OH), 8.76 (s, 1H, –NH), 7.81 (d, J= 7.3 Hz, 1H,Please cite this article in press as: Patel, D. et al., Synthesis and biological evaluation
Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2014.06.010coumarin), 7.74–7.19 (m, 8H, Ar–H), 6.63–6.56 (m, 3H, cou-
marin), 6.16 (s, 1H, coumarin); 13C NMR (DMSO-d6, d,
ppm): 162.67 (C‚O of coumarin), 159.65, 159.27 (2C, pyrim-
idine), 157.82 (C–OH), 148.87 (C–NH at coumarin), 113.18
(1C, pyrimidine), 147.88, 143.42, 133.76, 133.15, 131.30,
130.94, 130.45, 129.21, 128.76, 128.43, 124.60, 124.32, 119.41,
118.25, 118.10, 117.88, 92.85 (17C, Ar–C); EMI-MS (m/z):
477.65 (M+); Anal. Calcd for C25H15Cl2N3O3: C, 63.04; H,
3.17; N, 8.82. Found: C, 63.10; H, 3.12; N, 8.77.
2.8.3. 4-[4-(2-Hydroxy-6-p-tolyl-pyrimidin-4-yl)-
phenylamino]-chromen-2-one (80c)
Yield: 65%. m.p. 266–268 C; IR (KBr, cm1): 3280 (–NH),
3145 (–OH of pyrimidine), 1669 (C‚O of coumarin), 1561
(C‚N); 1H NMR (DMSO-d6, d, ppm): 9.90 (s, 1H, –OH),
8.82 (s, 1H, –NH), 7.77 (d, J= 7.5 Hz, 1H, coumarin), 7.71–
7.10 (m, 9H, Ar–H), 6.67–6.52 (m, 3H, coumarin), 6.19 (s,
1H, coumarin), 2.15 (s, 3H, Ph–CH3);
13C NMR (DMSO-d6,
d, ppm): 162.18 (C‚O of coumarin), 159.27, 159.13 (2C,
pyrimidine), 157.54 (C–OH), 149.52 (C–NH at coumarin),
139.04 (C–CH3 of phenyl), 113.07 (1C, pyrimidine), 148.65,
143.25, 132.88, 132.56, 131.65, 130.43, 129.79, 129.63, 129.11,
128.24, 127.82, 125.20, 124.16, 119.78, 118.40, 118.31, 117.23,
92.15 (18C, Ar–C), 22.55 (C–CH3 of phenyl); EMI-MS
(m/z): 422.69 (M+); Anal. Calcd for C26H19N3O3: C, 74.10;
H, 4.54; N, 9.97. Found: C, 74.14; H, 4.50; N, 9.92.
2.8.4. 4-{4-[6-(4-Fluoro-phenyl)-2-hydroxy-pyrimidin-4-yl]-
phenylamino}-chromen-2-one (80d)
Yield: 72%. m.p. >300 C; IR (KBr, cm1): 3277 (–NH), 3140
(–OH of pyrimidine), 1663 (C‚O of coumarin), 1569 (C‚N),
1163 (C–F); 1H NMR (DMSO-d6, d, ppm): 9.95 (s, 1H, –OH),
8.80 (s, 1H, –NH), 7.79 (d, J= 7.2 Hz, 1H, coumarin), 7.75–
7.14 (m, 9H, Ar–H), 6.72 – 6.59 (m, 3H, coumarin), 6.23
(s,1H, coumarin); 13C NMR (DMSO-d6, d, ppm): 168.13 (C–
F), 162.37 (C‚O of coumarin), 159.11, 158.87 (2C, pyrim-
idine), 157.22 (C–OH), 148.30 (C–NH at coumarin), 113.29
(1C, pyrimidine), 148.27, 143.13, 133.65, 133.37, 131.41,
130.11, 129.65, 129.23, 128.76, 128.34, 127.08, 124.45, 124.21,
119.36, 118.56, 118.15, 117.24, 93.54 (18C, Ar–C); EMI-MS
(m/z): 426.17 (M+); Anal. Calcd for C25H16FN3O3: C, 70.58;
H, 3.79; N, 9.88. Found: C, 70.64; H, 3.73; N, 9.80.
2.8.5. 4-{4-[6-(4-Chloro-phenyl)-2-hydroxy-pyrimidin-4-yl]-
phenylamino}-chromen-2-one (80e)
Yield: 77%. m.p. >300 C; IR (KBr, cm1): 3271 (–NH), 3137
(–OH of pyrimidine), 1660 (C‚O of coumarin), 1564 (C‚N),
827 (–Cl); 1H NMR (DMSO-d6, d, ppm): 9.88 (s, 1H, –OH),
8.78 (s, 1H, –NH), 7.75 (d, J= 7.5 Hz, 1H, coumarin), 7.71–
7.10 (m, 9H, Ar–H), 6.68–6.55 (m, 3H, coumarin), 6.13
(s,1H, coumarin); 13C NMR (DMSO-d6, d, ppm): 162.49
(C‚O of coumarin), 159.45, 159.20 (2C, pyrimidine), 157.39
(C–OH), 149.56 (C-NH at coumarin), 113.68 (1C, pyrimidine),
134.28 (C–Cl), 147.13, 143.24, 133.26, 132.43, 131.57, 130.43,
130.07, 129.71, 129.65, 128.42, 128.37, 123.69, 124.22, 119.41,
118.33, 118.11, 117.35, 92.40 (18C, Ar–C); EMI-MS (m/z):
442.55 (M+); Anal. Calcd for C25H16ClN3O3: C, 67.95; H,
3.65; N, 9.51. Found: C, 67.91; H, 3.60; N, 9.57.of coumarin based isoxazoles, pyrimidinthiones and pyrimidin-2-ones. Arabian
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phenylamino}-chromen-2-one (80f)
Yield: 66%. mp 246–249 C; IR (KBr, cm1): 3274 (–NH),
3140 (–OH of pyrimidine), 1668 (C‚O of coumarin), 1562
(C‚N), 1553 (N‚O str.); 1H NMR (DMSO-d6, d, ppm):
9.85 (s, 1H, –OH), 8.83 (s, 1H, –NH), 7.79 (d, J= 7.5 Hz,
1H, coumarin), 7.76–7.18 (m, 9H, Ar–H), 6.70–6.58 (m, 3H,
coumarin), 6.15 (s,1H, coumarin); 13C NMR (DMSO-d6, d,
ppm): 162.66 (C‚O of coumarin), 159.12, 158.34 (2C, pyrim-
idine), 157.22 (C–OH), 148.10 (C–NH at coumarin), 113.33
(1C, pyrimidine), 148.23 (C–NO2), 147.69, 143.13, 133.63,
132.40, 131.22, 130.17, 129.30, 129.22, 129.10, 128.87, 128.31,
124.75, 124.30, 119.21, 118.19, 117.75, 117.14, 93.12 (18C,
Ar–C); EMI-MS (m/z): 453.47 (M+); Anal. Calcd for
C25H16N4O5: C, 66.37; H, 3.56; N, 12.38. Found: C, 66.43;
H, 3.59; N, 12.31.
2.8.7. 4-{4-[2-Hydroxy-6-(2-hydroxy-phenyl)-pyrimidin-4-yl]-
phenylamino}-chromen-2-one (80g)
Yield: 78%. mp 233–236 C; IR (KBr, cm1): 3278 (–NH),
3239 (–OH), 3144 (–OH of pyrimidine), 1663 (C‚O of cou-
marin), 1556 (C‚N); 1H NMR (DMSO-d6, d, ppm): 9.76 (s,
1H, –OH), 8.78 (s, 1H, –NH), 7.82 (d, J= 7.2 Hz, 1H, cou-
marin), 7.78–7.22 (m, 9H, Ar–H), 6.66–6.51 (m, 3H, cou-
marin), 6.12 (s,1H, coumarin), 4.57 (s, 1H, –OH); 13C NMR
(DMSO-d6, d, ppm): 162.35 (C‚O of coumarin), 159.24,
159.15 (2C, pyrimidine), 157.87 (C–OH), 157.23 (C–OH),
149.34 (C–NH at coumarin), 113.45 (1C, pyrimidine), 149.09,
143.76, 133.45, 132.39, 131.11, 130.67, 130.33, 129.66, 129.17,
128.65, 128.61, 125.34, 124.55, 119.10, 118.25, 118.21, 117.53,
92.16 (18C, Ar–C); EMI-MS (m/z): 424.63 (M+); Anal.
Calcd for C25H17N3O4: C, 70.91; H, 4.05; N, 9.92. Found:
C, 70.97; H, 4.09; N, 9.85.
2.8.8. 4-{4-[6-(2-Bromo-phenyl)-2-hydroxy-pyrimidin-4-yl]-
phenylamino}-chromen-2-one (80h)
Yield: 71%. m.p. >300 C; IR (KBr, cm1): 3275 (–NH), 3148
(–OH of pyrimidine), 1661 (C‚O of coumarin), 1563 (C‚N),
723 (–Br); 1H NMR (DMSO-d6, d, ppm): 9.79 (s, 1H, –OH),
8.80 (s, 1H, -NH), 7.78 (d, J= 7.3 Hz, 1H, coumarin), 7.73–
7.13 (m, 9H, Ar–H), 6.70–6.58 (m, 3H, coumarin), 6.22
(s,1H, coumarin); 13C NMR (DMSO-d6, d, ppm): 162.27
(C‚O of coumarin), 159.10, 158.80 (2C, pyrimidine), 157.91
(C–OH), 148.67 (C–NH at coumarin), 113.37 (1C, pyrim-
idine), 121.98 (C–Br), 147.56, 143.86, 133.53, 133.19, 131.43,
130.22, 129.75, 129.19, 128.84, 128.40, 127.54, 124.35, 124.14,
119.49, 118.92, 118.39, 117.67, 93.14 (18C, Ar–C); EMI-MS
(m/z): 487.34 (M+); Anal. Calcd for C25H16BrN3O3: C,
61.74; H, 3.32; N, 8.64. Found: C, 61.78; H, 3.25; N, 8.69.
2.8.9. 4-{4-[2-Hydroxy-6-(4-methoxy-phenyl)-pyrimidin-4-yl]-
phenylamino}-chromen-2-one (80i)
Yield: 79%. m.p. >300 C; IR (KBr, cm1): 3277 (NH),
3143 (OH of pyrimidine), 1665 (C‚O of coumarin), 1560
(C‚N), 1270 (–OCH3);
1H NMR (DMSO-d6, d, ppm): 9.73
(s, 1H, –OH), 8.87 (s, 1H, –NH), 7.84 (d, J= 7.3 Hz, 1H, cou-
marin), 7.79–7.24 (m, 9H, Ar–H), 6.74–6.61 (m, 3H, cou-
marin), 6.26 (s,1H, coumarin), 3.71 (s, 3H, –OCH3);
13CPlease cite this article in press as: Patel, D. et al., Synthesis and biological evaluation
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161.13 (C–OCH3), 159.45, 158.24 (2C, pyrimidine), 157.67
(C–OH), 149.15 (C–NH at coumarin), 113.49 (1C, pyrim-
idine), 148.34, 143.75, 132.43, 131.77, 131.11, 130.56, 130.35,
129.55, 129.41, 128.63, 128.24, 125.65, 124.33, 119.41, 118.69,
118.51, 117.78, 93.12 (18C, Ar–C), 55.24 (–OCH3); EMI-MS
(m/z): 438.54 (M+); Anal. Calcd for C26H19N3O4: C, 71.39;
H, 4.38; N, 9.61. Found: C, 71.44; H, 4.32; N, 9.69.
2.8.10. 4-{4-[6-(3,4-Dimethoxy-phenyl)-2-hydroxy-pyrimidin-
4-yl]-phenylamino}-chromen-2-one (80j)
Yield: 73%. m.p. 278–280 C; IR (KBr, cm1): 3279 (–NH),
3147 (–OH of pyrimidine), 1670 (C‚O of coumarin), 1555
(C‚N), 1281 (-OCH3);
1H NMR (DMSO-d6, d, ppm): 9.81
(s, 1H, –OH), 8.82 (s, 1H, -NH), 7.79 (d, J= 7.4 Hz, 1H, cou-
marin), 7.73–7.13 (m, 8H, Ar–H), 6.69 – 6.56 (m, 3H, cou-
marin), 6.21 (s,1H, coumarin), 3.82 (s, 3H, -OCH3), 3.80 (s,
3H, –OCH3);
13C NMR (DMSO-d6, d, ppm): 162.33 (C‚O
of coumarin), 160.87 (C–OCH3), 161.14 (C–OCH3),159.24,
159.11 (2C, pyrimidine), 157.43 (C–OH), 148.23 (C–NH at
coumarin), 113.57 (1C, pyrimidine), 148.25, 143.51, 133.69,
132.44, 131.22, 130.26, 130.17, 129.43, 128.89, 128.45, 124.14,
124.11, 119.34, 118.64, 118.20, 117.30, 93.12 (17C, Ar–C),
55.83 (–OCH3); EMI-MS (m/z): 468.49 (M+); Anal. Calcd
for C27H21N3O5: C, 69.37; H, 4.53; N, 8.99. Found: C,
69.30; H, 4.59; N, 8.93.
2.8.11. 4-{4-[6-(2,4-Dihydroxy-phenyl)-2-hydroxy-pyrimidin-
4-yl]-phenylamino}-chromen-2-one (80k)
Yield: 75%. m.p. 253–256 C; IR (KBr, cm1): 3274 (–NH),
3257 (Ph–OH), 3138 (–OH of pyrimidine), 1666 (C‚O of cou-
marin), 1559 (C‚N); 1H NMR (DMSO-d6, d, ppm): 9.79 (s,
1H, –OH), 8.67 (s, 1H, Ph–OH), 8.77 (s, 1H, –NH), 7.75 (d,
J= 7.1 Hz, 1H, coumarin), 7.71–7.18 (m, 8H, Ar–H), 6.67–
6.58 (m, 3H, coumarin), 6.15 (s,1H, coumarin), 4.59 (s,1H,
Ph–OH); 13C NMR (DMSO-d6, d, ppm): 162.50 (C‚O of cou-
marin), 159.45, 159.32 (2C, pyrimidine), 157.69, 157.62 (2C,
Ph–C–OH), 157.34 (C–OH of pyrimidine), 148.67 (C–NH at
coumarin), 113.79 (1C, pyrimidine), 148.55, 143.24, 133.67,
132.21, 131.49, 130.67, 129.32, 129.11, 128.89, 127.31, 125.58,
124.47, 119.41, 118.25, 118.10, 117.78, 92.13 (17C, Ar–C),
(17C, Ar–C); EMI-MS (m/z): 440.35 (M+); Anal. Calcd for
C25H17N3O5: C, 68.33; H, 3.90; N, 9.56. Found: C, 68.27; H,
3.95; N, 9.52.2.9. Antimicrobial assay
The synthesized compounds 60a–k, 70a–k, 80a–k were examined
for antimicrobial activity against several bacterial
(Staphylococcus aureus MTCC 96, Bacillus cereus MTCC
430, Escherichia coli MTCC 739, Pseudomonas aeruginosa
MTCC 741, Klebsiella pneumoniae MTCC 109, Salmonella
typhi MTCC 733, Proteus vulgaris MTCC 1771, Shigella
Flexneri MTCC 1457) and fungal (Aspergillus niger MTCC
282, Aspergillus fumigatus MTCC 343, Aspergillus clavatus
MTCC 1323, Candida albicansMTCC 183) species using paper
disk diffusion technique (Gillespie, 1994). The sterilized (auto-
claved at 120 C for 30 min) medium (40–50 C) was inocu-
lated (1 ml/100 ml of medium) with the suspensionof coumarin based isoxazoles, pyrimidinthiones and pyrimidin-2-ones. Arabian
8 D. Patel et al.(105 cfu ml1) of the micro-organism (matched to McFarland
barium sulfate standard) and poured into a petridish to give
a depth of 3–4 mm. The paper impregnated with the test com-
pounds (lg ml1) in dimethyl sulfoxide was placed on the
solidiﬁed medium. The plates were pre-incubated for 1 h at
room temperature and incubated at 37 C for 24 and 48 h
for anti-bacterial and anti-fungal activities, respectively.
Ciproﬂoxacin (100 lg/disk) and Ketoconazole (100 lg/disk)
were used as standard for antibacterial and anti-fungal activi-
ties, respectively. The observed zone of inhibition is presented
in Tables 1–3. MIC of the compound was determined by the
agar streak dilution method (Hawkey and Lewis, 1994). A
stock solution of the synthesized compound (100 lg ml1) in
dimethyl sulfoxide was prepared and graded quantities of the
test compounds were incorporated in speciﬁed quantity of
molten sterile agar (nutrient agar for anti-bacterial activity
and sabouraud dextrose agar medium for anti-fungal activity).
A speciﬁed quantity of the medium (40–50 C) containing the
compound was poured into a petridish to give a depth ofTable 1 In vitro antibacterial activity of newly synthesized compou
Compound Zone of inhibition [mm (MIC in lg/mL)]
S.a B.c E.c P.a
60a 12 (100) 15 (100) 11 (100) <10 (1
60b 20 (25) 22 (12.5) 19 (25) 21 (12.
60c 18 (50) 17 (50) 16 (100) 14 (100
60d 21 (12.5) 23 (12.5) 18 (50) 22 (25)
60e 17 (50) 20 (50) 12 (100) 10 (100
60f 10 (100) 13 (100) 17 (100) 13 (100
60g 19 (50) 18 (50) 17 (100) 12 (100
60h 12 (100) 11 (100) 15 (100) 10 (100
60i 19 (50) 16 (100) 17 (100) 13 (100
60j 22 (12.5) 20 (25) 23 (12.5) 18 (50)
60k 17 (50) 19 (50) 23 (6.25) 20 (50)
70a 17 (100) 14 (100) 17 (100) 16 (100
70b 25 (6.25) 23 (12.5) 21 (25) 19 (50)
70c 20 (25) 17 (50) 13 (100) 14 (100
70d 25 (6.25) 28 (3.12) 26 (6.25) 24 (12.
70e 25 (6.25) 24 (12.5) 23 (12.5) 21 (25)
70f 19 (50) 23 (12.5) 21 (25) 17 (50)
70g 22 (12.5) 21 (12.5) 18 (50) 22 (12.
70h 21 (25) 22 (12.5) 17 (100) 18 (50)
70i 28 (3.12) 25 (6.25) 22 (12.5) 26 (6.2
70j 25 (6.25) 28 (3.12) 24 (12.5) 27 (6.2
70k 24 (12.5) 25 (6.25) 28 (3.12) 23 (12.
80a 15 (100) 11 (100) 12 (100) 14 (100
80b 22 (12.5) 21 (25) 18 (50) 20 (50)
80c 21 (25) 19 (50) 10 (100) 21 (25)
80d 22 (12.5) 25 (6.25) 24 (12.5) 21 (25)
80e 22 (12.5) 23 (12.5) 21 (25) 22 (25)
80f 17 (50) 21 (25) 18 (50) 14 (100
80g 23 (12.5) 21 (25) 22 (12.5) 13 (100
80h 17 (100) 23 (12.5) 19 (50) 23 (12.
80i 27 (6.25) 23 (12.5) 21 (25) 22 (12.
80j 27 (6.25) 26 (6.25) 24 (12.5) 27 (6.2
80k 23 (12.5) 26 (6.25) 26 (6.25) 21 (25)
Ciproﬂoxacin 30 (1.0) 31 (1.0) 32 (1.0) 33 (1.0
DMSO – – – –
S.a. – Staphylococcus aureus, B.c. – Bacillus cereus, E.c. – Escherichia col
Salmonella typhi, P.v. – Proteus vulgaris, S.f. – Shigella ﬂexneri.
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organism was prepared to contain approximately 105 cfu ml1-
and applied to plates with serially diluted compounds in
dimethyl sulfoxide to be tested and incubated at 37 C for 24
and 48 h for bacteria and fungi, respectively. The MIC was
considered to be the lowest concentration of the test substance
exhibiting no visible growth of bacteria or fungi on the plate.
The observed MIC is presented in Tables 1 and 2.
2.10. Antimycobacterial assay
The antimycobacterial screening for test compounds was per-
formed against M. tuberculosis H37Rv using the L.J.
(Lowenstein and Jensen) MIC method (Isenberg, 1992) for
the measurement of MIC. Stock solutions of primary 1000,
500, 250, and secondary 200, 100, 62.5, 50, 25, 12.5, 6.25,
3.25 lg/mL dilutions of each test compound in dimethylsulfox-
ide (DMSO) were added in the liquid L.J. Medium and then
media were sterilized by the inspissation method. A culturends 60a–80k.
K.p S.t P.v S.f
00) <10 (100) 11 (100) <10 (100) 10 (100)
5) 18 (50) 16 (50) 19 (25) 15 (100)
) 19 (50) 11 (100) 21 (25) 14 (100)
22 (25) 17 (50) 23 (12.5) 18 (50)
) 20 (50) 14 (100) 13 (100) 22 (50)
) 15 (100) 10 (100) <10 (100) 12 (100)
) 15 (100) 13 (100) 11 (100) 20 (50)
) 13(100) 12 (100) 11 (100) 10 (100)
) 20 (50) 14 (100) 13 (100) 20 (50)
21 (25) 18 (50) 18 (50) 21 (25)
21 (25) 19 (50) 20 (25) 22 (25)
) 12 (100) 19 (50) 19 (50) 11 (100)
22 (25) 21 (25) 20 (12.5) 22 (25)
) 12 (100) 21 (25) 22 (25) 18 (50)
5) 28 (3.12) 23 (12.5) 26 (6.25) 24 (12.5)
24 (12.5) 26 (6.25) 21 (25) 20 (25)
21 (25) 19 (50) 20 (50) 20 (50)
5) 24 (12.5) 15 (100) 17 (100) 21 (12.5)
19 (50) 23 (12.5) 19 (50) 23 (12.5)
5) 21 (25) 23 (12.5) 24 (12.5) 25 (6.25)
5) 26 (6.25) 21 (25) 24 (12.5) 26 (6.25)
5) 26 (6.25) 23 (12.5) 28 (3.12) 23 (12.5)
) 10 (100) 11 (100) 15 (100) 19 (50)
20 (50) 21 (25) 23 (12.5) 22 (25)
15 (100) 18 (50) 21 (25) 19 (50)
25 (6.25) 20 (50) 23 (12.5) 24 (12.5)
26 (6.25) 23 (12.5) 18 (50) 21 (25)
) 19 (50) 18 (50) 18 (50) 22 (25)
) 21(12.5) 13 (100) 11 (100) 21 (12.5)
5) 18 (50) 21 (12.5) 19 (50) 22 (12.5)
5) 19 (50) 22 (12.5) 21 (25) 24 (12.5)
5) 22 (12.5) 21 (12.5) 23 (12.5) 22 (12.5)
26 (6.25) 22 (25) 26 (6.25) 22 (25)
) 33 (1.0) 30 (1.0) 31 (1.0) 32 (63)
– – – –
i, P.a. – Pseudomonas aeruginosa, K.p. – Klebsiella pneumoniae, S.t. –
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Table 2 In vitro antifungal activity of newly synthesized compounds 60a-80k.
Compound Zone of inhibition in mm (MIC in lg/mL)
A. n. A. f. A. c. C. a.
60a 14 (100) 11 (100) 10 (100) 11 (100)
60b 13 (100) 15 (100) 11 (100) 10 (100)
60c 16 (100) 17 (50) 15 (100) 12 (100)
60d 16 (100) 22 (25) 22 (25) 19 (50)
60e 18 (50) 14 (100) 12 (100) 21 (25)
60f 16 (100) 17 (100) 19 (50) 19 (50)
60g 21 (25) 12 (100) 21 (25) 14 (100)
60h 22 (25) 22 (25) 11 (100) 22 (25)
60i 19 (50) 17 (100) 18 (50) 18 (50)
60j 21 (50) 18 (50) 22 (25) 19 (50)
60k 25 (12.5) 23 (12.5) 22 (25) 20 (50)
70a 19 (50) 20 (25) 24 (12.5) 18 (50)
70b 22 (12.5) 20 (50) 22 (12.5) 20 (50)
70c 17 (50) 20 (25) 13 (100) 18 (50)
70d 28 (6.25) 22 (12.5) 21 (25) 23 (12.5)
70e 26 (6.25) 24 (12.5) 20 (25) 24 (12.5)
70f 22 (25) 22 (25) 24 (12.5) 19 (50)
70g 24 (25) 27(6.25) 25 (12.5) 23 (25)
70h 19 (25) 24 (25) 23 (12.5) 19 (25)
70i 24 (12.5) 25 (6.25) 23 (12.5) 23 (12.5)
70j 27 (6.25) 27 (6.25) 28 (3.12) 27 (6.25)
70k 22 (12.5) 23 (12.5) 27 (6.25) 22 (12.5)
80a 17 (100) 18 (50) 21 (25) 13 (100)
80b 21 (25) 18 (50) 20 (50) 22 (12.5)
80c 18 (50) 23 (12.5) 15 (100) 20 (50)
80d 24 (12.5) 23 (12.5) 20 (50) 21 (12.5)
80e 20 (25) 22 (12.5) 17 (50) 19 (50)
80f 20 (50) 21 (25) 20 (50) 16 (100)
80g 17 (50) 24 (12.5) 21 (25) 21 (25)
80h 18 (50) 20 (50) 21 (12.5) 17 (50)
80i 22 (12.5) 27 (6.25) 24 (12.5) 27 (6.25)
80j 26 (6.25) 24 (12.5) 26 (6.25) 21 (12.5)
80k 23 (12.5) 20 (25) 24 (12.5) 19 (50)
Ketoconazole 30 (63) 29 (1.0) 31 (1.0) 33 (1.0)
DMSO – – – –
A.n. – Aspergillus niger, A.f. – Aspergillus fumigatus, A.c. – Aspergillus clavatus, C.a. – Candida albicans.
Synthesis of coumarin based isoxazoles, pyrimidinthiones and pyrimidin-2-ones 9of M. tuberculosis H37Rv growing on the L.J. medium was
harvested in 0.85% saline in bijou bottles. These tubes were
then incubated at (37 ± 1) C for 24 h followed by streaking
of M. tuberculosis H37Rv (5 · 104 bacilli per tube). Growth
of bacilli was seen after 12 days, 22 days and ﬁnally 28 days
of incubation. Tubes having the compounds were compared
with control tubes where medium alone was incubated with
M. tuberculosis H37Rv. The concentration at which no devel-
opment of colonies or <20 colonies occurred was taken as
MIC concentration of the test compound. The standard strain
M. tuberculosis H37Rv was tested with known drugs rifampi-
cin, isoniazid, ethambutol and pyrazinamide.
3. Results and discussion
3.1. Chemistry
Synthetic route of isoxazoles, pyrimidinthiones and pyrimidin-
2-ones is depicted in Scheme 1. The target compounds were
obtained from coumarin based chalcones 5a–k and theirPlease cite this article in press as: Patel, D. et al., Synthesis and biological evaluation
Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2014.06.010cyclization with hydroxyl amine hydrochloride, thiourea and
urea led to the formation of corresponding isoxazoles (60a–
k), pyrimidinthiones (70a–k) and pyrimidin-2-ones (80a–k).
The presence of singlet signal at 7.81 ppm for one proton of
–CH in 1H NMR spectra and band at 1588 cm1 for C‚N
in IR spectrum conﬁrms the formation of isoxazole compound
6’a. 13C NMR data showed peak at 168.23, 164.27 and
97.54 ppm for corresponding carbons of C–O, C‚N and –
CH of isoxazole respectively. The singlet signal observed at
9.83 ppm in 1H NMR spectra of compound 70a was attributed
to –SH of pyrimidine ring. In addition, the band at 1571 cm1
(–SH str.) also conﬁrmed the formation of compound 70a. In
13C NMR data, peak at 176.11 ppm was observed for C–SH
of 70a. Compound 80a showed singlet peak at 9.83 ppm for
one proton of –OH of pyrimidine ring and appearance of the
–OH group at 3145 cm1 in IR spectra conﬁrmed the forma-
tion of pyrimidin-2-one ring. The presence of carbon of C–
OH at pyrimidine ring was conﬁrmed by appearance of peak
at 157.23 ppm.of coumarin based isoxazoles, pyrimidinthiones and pyrimidin-2-ones. Arabian
Table 3 In vitro antimycobacterial activity of newly synthe-
sized compounds 60a–80k.
Compound MIC in lg/mL % Inhibition
60a 1000 95
60b 250 97
60c 500 96
60d 200 98
60e 500 96
60f 1000 95
60g 200 98
60h 250 97
60i 200 98
60j 62.5 99
60k 100 98
70a 250 97
70b 50 99
70c 62.5 99
70d 100 98
70e 250 97
70f 250 97
70g 25 99
70h 200 97
70i 100 98
70j 25 99
70k 100 97
80a 1000 95
80b 200 97
80c 100 98
80d 250 98
80e 500 96
80f 1000 95
80g 100 99
80h 250 96
80i 100 98
80j 62.5 99
80k 250 98
Ethambutol 3.12 99
Pyrazinamide 6.25 99
Rifampicin 0.25 99
Isoniazid 0.20 99
10Ar (a–k) – Aromatic aldehydes
CHO
CHOH3C
CHOF
CHOO2N
CHO
Br
CHOHO
OH
a
b
c
d
e
f
g
h
i
k
CHOCl
Cl
CHOCl
CHO
CHOH3CO
CHOH3CO
H3CO
j
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Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2014.06.0103.2. Antimicrobial activityInvestigation on antimicrobial screening data (Tables 1 and 2)
of target compounds resulted in a good deal of activity against
all the mentioned bacteria and fungi. The obtained results gen-
erally indicate that the majority of these series of compounds
are more active against Gram-positive and Gram-negative bac-
teria than the fungi.
3.2.1. Antimicrobial activity of isoxazole analogs
Compound 60b having chloro substituents on ortho and para
positions of aryl ring at isoxazole moiety displayed the best
activity in terms of MIC = 12.5 lg/mL against B. cereus and
P. aeruginosa, beside one compound 60d having ﬂuoro sub-
stituent at para position of aryl ring showed similar
MIC = 12.5 lg/mL with 23 mm of inhibitory zone against
B. cereus. Compound 60d was also found most active among
all the isoxazole analogs in terms of MIC and zone of inhibi-
tion against K. pneumonia and P. vulgaris. Gram-positive bac-
teria S. aureus were strongly inhibited by compound 60h having
an electron donating methoxy substituent at meta–para posi-
tion of aryl ring. Hydroxy substituted compound 60k exerted
excellent MIC = 6.25 lg/mL against E. coli and also showed
maximum zone of inhibition (19 mm) against S. typhi among
all the isoxazole analogs. In antifungal data compound 60k
showed superior results than the other isoxazoles against A.
niger, A. fumigates and A. clavatus, while the bromo group
containing compound 60h displayed the highest activity
(MIC = 25 lg/mL, inhibition zone = 22 mm) against C.
albicans.
3.2.2. Antimicrobial activity of pyrimidinthione analogs
In general most of the pyrimidinthiones showed better activity
than the isoxazole analogs as some of the ﬁnal pyrim-
idinthiones showed good MIC range of 3.12–25 lg/mL against
bacterial strains. Most of the pyrimidinthiones were observed
for their noticeable antibacterial activity against Gram-
positive bacteria. Compound 70i having the mono methoxy
group at para position of aryl ring at pyrimidine moiety
showed excellent activity (MIC = 3.12 lg/mL, inhibition
zone = 28 mm) against S. aureus. Against the same bacteria,
analogs 70b, 70d, 70e and 70j displayed signiﬁcant
MIC = 6.25 lg/mL. The highest activity compared to other
pyrimidinthiones against B. cereus, K. pneumoniae, and S.
typhi was displayed by compound 70d, besides one compound
70j demonstrates similar activity compared to the most potent
compound 70d against B. cereus. Furthermore, compound 70j
showed potential inhibitory efﬁcacy against P. aeruginosa
and S. ﬂexneri at 6.25 lg/mL of MIC. Bacteria E. coli and
P. vulgaris were strongly inhibited by compound 70j with
MIC = 3.12 lg/mL and with maximum inhibitory zone of
28 mm and same compound was observed for signiﬁcant
MIC range (6.25–12.5 lg/mL) against other bacterial strain.
In case of antifungal activity compounds 70d, 70e and 70j inhibit
the E. coli at MIC = 6.25 lg/mL, but 70d showed quite an
increased inhibitory zone than 70e and 70j. The MIC range of
3.12–6.15 lg/mL of analog 70j indicates that it exhibited as
most active compound against all the fungal strains, specially
against A. clavatus and C. albicans. None of the compounds
showed similar MIC and zone of inhibition against A. clavatus
and C. albicans like 70j.
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The results of antimicrobial screening revealed that the
pyrimidin-2-one analogs in some cases were found to show
better activity than the isoxazoles and quite lesser activity than
the pyrimidinthiones. Analogs 80d, 80I and 80j, 80k were found
to display most signiﬁcant MIC (6.25–12.5 lg/mL) against
both the Gram-positive bacteria than other pyrimidin-2-ones.
Only one compound 80k inhibits E. coli, K. pneumonia, and
P. vulgaris at MIC = 6.25 lg/mL with 26 mm of inhibitory
zone, except compound 80e having mono chloro substituent
at aryl ring that showed similar activity against K. pneumonia.
The best MIC (12.5 lg/mL) value against S. ﬂexneri was dis-
played by derivatives 80d, 80g, 80h, 80I and 80j. Antifungal data
of pyrimidin-2-ones determine that only two derivatives 80I
and 80j exhibit MIC in the range of 6.25–12.5 lg/mL againstPlease cite this article in press as: Patel, D. et al., Synthesis and biological evaluation
Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2014.06.010all the fungal strains. Among all the pyrimidin-2-one analogs,
compounds 80I and 80j were found most active against A. fumi-
gates and C. albicans with MIC = 6.25 lg/mL and 27 mm of
zone of inhibition, while 80j was observed for the same against
A. niger and A. clavatus with similar MIC (6.25 lg/mL) and
26 mm of inhibitory zone.
3.3. Antimycobacterial activity
The results of the in vitro antimycobacterial activity of synthe-
sized compounds against M. tuberculosis H37 RV were
obtained from the Lowenstein Jensen MIC method and the
measurement of potency of the analogs and standard drugs
is shown in Table 3. Analogs 60j, 70b, 70c, 70g, 70j, and 80j
showed MIC value below 100 lg/mL, in which 70g and 70jof coumarin based isoxazoles, pyrimidinthiones and pyrimidin-2-ones. Arabian
12 D. Patel et al.displayed signiﬁcant MIC = 25 lg/mL with 99% inhibition,
while rest of the compounds showed MIC in the range of
100–1000 lg/mL. None of the compounds were potent as stan-
dard drugs.
4. Conclusion
The series of coumarin containing isoxazoles, pyrimidinthiones
and pyrimidin-2-ones with an electron donating/withdrawing
functionality at phenyl ring have been synthesized in
appreciable yield and spectral data were found in agreement
with the assigned molecular structures. Generally among the
synthesized series, most of the tested compounds exhibited
pronounced antimicrobial activities comparable to reference
drugs. Some of the ﬁnal scaffolds showed MIC =
3.12 lg/mL against the bacterial strain and 6.25–12.5 lg/mL
against fungal species which are comparable to the standard
drugs. In addition, among all three series the methoxy group
containing compounds 6’j, 7’j and 8’j showed MIC level at
25–62.5 lg/mL with 99% of inhibition for antimycobacterial
activity. These data are consistent with our previous ﬁndings
and indicate that coumarin moiety with isoxazoles, pyrim-
idinthiones and pyrimidin-2-ones is clearly essential for the
biological signiﬁcance.
References
Batra, S., Sharma, S., 1990. Indian J. Chem. 29B, 1051.
Batra, S., Roy, A.K., Patra, A., Bhaduri, A.P., Surin, W.R.,
Raghavan, S.A.V., Sharma, P., Kapoorb, K., Dikshitb, M., 2004.
Bioorg. Med. Chem. 12, 2059.
Baucer, V., Dalalian, H., Saﬁr, S., 1968. J. Med. Chem. 11, 1263.
Dinakaran, V.S., Jacob, D., Mathew, J.E., 2012. Med. Chem. Res. 21,
3598.Please cite this article in press as: Patel, D. et al., Synthesis and biological evaluation
Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2014.06.010Gillespie, S.H., 1994. Medical Microbiology-Illustrated. Butterworth
Heinemann Ltd., United Kingdom, 234.
Hawkey, P.M., Lewis, D.A., 1994. Medical Bacteriology – A Practical
Approach. Oxford University Press, United Kingdom, 181.
Isenberg, H.D., 1992. In: Clinical Microbiology Procedures
Handbook, vol. 1. American Society for Microbiology,
Washington, D.C..
Karabasanagouda, T., Adhikari, A.V., Girisha, M., 2009. Indian J.
Chem. B. 48B, 430.
Karthikeyan, K., Veenus Seelan, T., Lalitha, K.G., Perumal, P.T.,
2009. Bioorg. Med. Chem. Lett. 19, 3370.
Kova´cˇ, M., Sabatie´, A., Floch, L., 2001. Arkivoc 6, 100.
Kumbhare, R.M., Kosurkar, U.B., Janaki Ramaiah, M., Dadmal,
T.L., Pushpavalli, S.N.C.V.L., Pal-Bhadra, M., 2012. Bioorg. Med.
Chem. Lett., 5424
Lanjewar, K.R., Rahatgaonkar, A.M., Chorghade, M.S., Saraf, B.D.,
2009. Indian J. Chem. 48B, 1732.
Musad, E.A., Mohamed, R., Saeed, B.A., Vishwanath, B.S.,
Lokanatha Rai, K.M., 2011. Bioorg. Med. Chem. Lett. 21, 3536.
Nagarajaiah, H., Khazi, I.M., Begum, N.S., 2012. J. Chem. Sci. 124,
847.
Ozaki, 1984. Chem. Abstr. 101, 55035.
Patel, D., Kumari, P., Patel, N., 2012. Med. Chem. Res. 21, 2926.
Patel, D., Kumari, P., Patel, N., 2012. Med. Chem. Res., 11 http://
dx.doi.org/10.1007/s00044-012-0073-3.
Russel, R., Press, J., Rampulla, R., Mc Nally, J., 1988. J. Med. Chem.
31, 1786.
Saleh, M., Abbott, S., Lauzon, V.C., Penney, C., Zacharie, B., 2010.
Bioorg. Med. Chem. Lett. 20, 945.
Shailaja, M., Manjula, A., Rao, B.V., 2011. Indian J. Chem. B. 50B,
214–222.
Tibor, M., Neil, P.S., Henry, S.P., 1994. Chem. Abstr. 121, 255784t.
Tomit, K., Takahi, Y., Vdaira, H., 1973. Ann. Sankyo Res. Lab. 1, 25.
World Health Organization, Global tuberculosis control: a short
update to the 2009 report. Available from: <http://www.who.int/
tb/publications/global_report/2009/update/en/index.html>.of coumarin based isoxazoles, pyrimidinthiones and pyrimidin-2-ones. Arabian
